Akademik Veri Yönetim Sistemi
ARCHIVES OF DERMATOLOGICAL RESEARCH, cilt.317, sa.1, 2025 (SCI-Expanded)
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with systemic involvement. Emerging biomarkers like the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV) may complement conventional markers (CRP, ESR) in assessing disease severity, but their role during biologic therapy remains unclear. To evaluate adalimumab's impact on novel inflammatory biomarkers and their association with HS severity. This retrospective study analyzed patients with Hurley stage 2-3 HS treated with >= 6 months of adalimumab. SII, SIRI, PIV, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) were assessed at baseline, month 3, and month 6. Clinical severity was measured by fistula and abscess counts, and treatment response was evaluated using the Hidradenitis Suppurativa Clinical Response (HiSCR) criteria. Patient-reported outcomes included the Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). The study included 97 patients classified as Hurley stage 2 (29.9%) and stage 3 (70.1%). Stage 3 patients had higher CRP, ESR, DLQI, and HADS-A scores (P < 0.001). Treatment significantly reduced clinical (fistula, abscess), hematologic (neutrophils, monocytes, platelets, MPV), and inflammatory markers (NLR, PLR, MLR, SIRI, SII, PIV) (P < 0.001), while lymphocytes increased (P < 0.001). MLR was the only independent predictor of severe disease (P = 0.019). Baseline biomarkers did not predict treatment response. Reductions in MLR correlated with decreases in abscess and total lesion counts, and PLR and PIV reductions correlated with abscess count reduction. Biomarker changes did not differ significantly between responders and non-responders. MLR was the only independent predictor of HS severity and showed significant correlation with clinical improvement. MLR may serve as a cost-effective, easily accessible biomarker to complement clinical assessment in HS.